Substituted naphthylacetic acids
AssigneeHoffmann-La Roche Inc.
InventorsFariborz Firooznia, Tai-An Lin, Eric Mertz, Sung-Sau So, Achyutharao Sidduri, Jefferson Wright Tilley
Life of this patent
Estimating the term…
Abstract
The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
Claims23
A compound of formula (I):
- wherein:
- X is —SO2—, —SO2NH—, —NHSO2—, —NHC(O)— or —NHC(O)NH—;
- Y is N or CH;
- R1 is halogen;
- R2 is -phenyl, unsubstituted or mono- or bi-substituted independently with lower alkyl, halogen, alkoxy, —SO2-lower alkyl, haloalkyl or —OCF3,
- unsubstituted heteroaryl,
- lower alkyl, unsubstituted or substituted with hydroxy, unsubstituted phenyl or phenyl substituted with halogen, —SO2-lower alkyl or alkoxy,
- unsubstituted cycloalkyl,
- unsubstituted heterocycloalkyl, or
- N(lower alkyl)2, said lower alkyl independently being unsubstituted or substituted with unsubstituted phenyl or phenyl substituted with methoxy;
- and
- R3 is lower alkyl or hydrogen,
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.